Thus, inhibiting the IL-6 pathway may result in synergistic effects by (a) augmenting antiproliferative effects and (b) prevention of sensory neuropathy with subsequent dose-alterations. The gene discussed is IL6; the disease is sensory peripheral neuropathy.